Hier finden Sie die Publikationen ab 2010, die am IfADo entstanden sind.
Selective genetic inactivation of Caspase 8 in hepatocytes ameliorates progression of MASH following Jnk deficiency. Hepatology. 2025. doi: 10.1097/HEP.0000000000001286. Epub ahead of print.
Improved identification of human hepatotoxic potential by summary variables of gene expression. ALTEX. 2025. doi: 10.14573/altex.2403272. Epub ahead of print.
Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis. J Hepatol 80: 268-281 (2024)
Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression. JHEP Rep 6 (3): 100987 (2024) (14 pp)
EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis. Breast Cancer Res 26(1): 87 (2024) (20 pp)
Risk assessment of parabens in a transcriptomics-based in vitro test. Chem Biol Interact 384: 110699 (2023)
Increased sinusoidal export of drug glucuronides is a compensative mechanism in liver cirrhosis of mice. Front Pharmacol 14: 1279357 (2023) (14 pp)
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth. J Exp Clin Cancer Res 42 (1): 25 (2023) (18 pp)
Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis. Nat Commun 14 (1): 3304 (2023) (17 pp)